Immune Thrombocytopenic Purpura Therapeutics Market Report

Global and Region Immune Thrombocytopenic Purpura Therapeutics Market Demand & Opportunity Outlook 2022-2028

  • POSTDATE：Aug 03, 2022
  • PAGES：159
  • REPORT CODE：GMM1016940
  • REPORT SUMMARY
  • TABLE OF CONTENTS

  • The report details the trend, potential and market size of Immune Thrombocytopenic Purpura Therapeutics market, and analyzes the current situation and prospects of the market from both qualitative and quantitative aspects, which can be roughly divided into three parts.

    The first part (Chapter1-7) mainly covers the qualitative analysis of Immune Thrombocytopenic Purpura Therapeuticsmarket, defines the market attractiveness level of Immune Thrombocytopenic Purpura Therapeutics market through Porter's Five Forces Analysis, and summarizes the different factors in the overall environment through PEST analysis. Understand the distribution of industrial chain value in each link of industrial chain through the analysis of industrial chain structure. Thus estimate the market space of each link.

    The second part (Chapter8-12), based on the segmentation of Immune Thrombocytopenic Purpura Therapeutics industry, describes the types of Immune Thrombocytopenic Purpura Therapeutics market, the applications of major players and the market size, and deeply analyzes the current situation of the global Immune Thrombocytopenic Purpura Therapeutics market and the development prospects and opportunities of Immune Thrombocytopenic Purpura Therapeutics industry.

    The third part (Chapter14-15) includes the market positions of the major players and information on the market participants, which will help you gain a comprehensive understanding of the current competitive situation and potential growth opportunities in the market.

    As COVID-19 continues to impact the global economy in 2022, the report also considers the short - and long-term impacts of COVID-19 on the global Immune Thrombocytopenic Purpura Therapeutics market in Chapter 13.

    By Player:

    • Baxalta Incorporated

    • Bristol-Myers Squibb Company

    • Momenta Pharmaceuticals, Inc

    • Boehringer Ingelheim GmbH

    • Amgen Inc

    • Hansa Medical AB

    • Eisai

    • Intas Pharmaceuticals Ltd

    • Pfizer Inc

    • Immunomedics, Inc

    • Novartis AG

    • Jiangsu Hengrui Medicine Co, Ltd

    • Merck & Co, Inc

    By Type:

    • Eltrombopag Olamine

    • Fostamatinib Disodium

    • GL-2045

    • Avatrombopag

    • BI-655064

    • Others

    By End-User:

    • Hospital

    • Clinic

    • Others

    By Geography:

    • United States

    • Europe

    • China

    • Japan

    • India

    • South Korea

  • TABLE OF CONTENT

    1 Introduction

    • 1.1 Market Definition

    • 1.2 Market Segment Analysis

    • 1.3 Market Size 2022

    • 1.4 Immune Thrombocytopenic Purpura Therapeutics Market Outlook: Forecast for 2022 - 2028

    • 1.5 Pricing Analysis

    2 Executive Summary

    3 Immune Thrombocytopenic Purpura Therapeutics Market Lineage Outlook

    • 3.1 Parent Market Outlook

    • 3.2 Related/Ancillary Market Outlook

    • 3.3 Penetration & Growth Prospect Mapping, 2022

    4 Market Analysis Tools: Porter's Five Forces

    • 4.1 Supplier Power

    • 4.2 Buyer Power

    • 4.3 Substitution Threat

    • 4.4 Threat of New Entrants

    • 4.5 Competitive Rivalry

    5 Immune Thrombocytopenic Purpura Therapeutics Industry Analysis - PEST (Political & Legal, Economic, Social, and Technological)

    • 5.1 Political/Legal Landscape

    • 5.2 Economic Landscape

    • 5.3 Social Landscape

    • 5.4 Technology Landscape

    6 Immune Thrombocytopenic Purpura Therapeutics Market - Value Chain Analysis

    • 6.1 Industry's Value Chain Analysis

    • 6.2 Product Life Cycle

    • 6.3 User Perspective Analysis

    7 Region and Country-wise Immune Thrombocytopenic Purpura Therapeutics Market Analysis and Outlook to 2022

    • 7.1 Global Immune Thrombocytopenic Purpura Therapeutics Consumption (2017-2022)

    • 7.2 United States Immune Thrombocytopenic Purpura Therapeutics Consumption (2017-2022)

    • 7.3 Europe Immune Thrombocytopenic Purpura Therapeutics Consumption (2017-2022)

    • 7.4 China Immune Thrombocytopenic Purpura Therapeutics Consumption (2017-2022)

    • 7.5 Japan Immune Thrombocytopenic Purpura Therapeutics Consumption (2017-2022)

    • 7.6 India Immune Thrombocytopenic Purpura Therapeutics Consumption (2017-2022)

    • 7.7 South Korea Immune Thrombocytopenic Purpura Therapeutics Consumption (2017-2022)

    8 Region and Country-wise Immune Thrombocytopenic Purpura Therapeutics Market Analysis and Outlook to 2028

    • 8.1 Global Immune Thrombocytopenic Purpura Therapeutics Consumption Forecast (2022-2028)

    • 8.2 United States Immune Thrombocytopenic Purpura Therapeutics Consumption Forecast (2022-2028)

    • 8.3 Europe Immune Thrombocytopenic Purpura Therapeutics Consumption Forecast (2022-2028)

    • 8.4 China Immune Thrombocytopenic Purpura Therapeutics Consumption Forecast (2022-2028)

    • 8.5 Japan Immune Thrombocytopenic Purpura Therapeutics Consumption Forecast (2022-2028)

    • 8.6 India Immune Thrombocytopenic Purpura Therapeutics Consumption Forecast (2022-2028)

    • 8.7 South Korea Immune Thrombocytopenic Purpura Therapeutics Consumption Forecast (2022-2028)

    9 Global Immune Thrombocytopenic Purpura Therapeutics Market Outlook by Types and Applications to 2022

    • 9.1 Global Immune Thrombocytopenic Purpura Therapeutics Consumption and Growth Rate by Type (2017-2022)

      • 9.1.1 Global Eltrombopag Olamine Consumption and Growth Rate (2017-2022)

      • 9.1.2 Global Fostamatinib Disodium Consumption and Growth Rate (2017-2022)

      • 9.1.3 Global GL-2045 Consumption and Growth Rate (2017-2022)

      • 9.1.4 Global Avatrombopag Consumption and Growth Rate (2017-2022)

      • 9.1.5 Global BI-655064 Consumption and Growth Rate (2017-2022)

      • 9.1.6 Global Others Consumption and Growth Rate (2017-2022)

    • 9.2 Global Immune Thrombocytopenic Purpura Therapeutics Consumption and Growth Rate by Application (2017-2022)

      • 9.2.1 Global Hospital Consumption and Growth Rate (2017-2022)

      • 9.2.2 Global Clinic Consumption and Growth Rate (2017-2022)

      • 9.2.3 Global Others Consumption and Growth Rate (2017-2022)

    10 Global Immune Thrombocytopenic Purpura Therapeutics Market Outlook by Types and Applications to 2028

    • 10.1 Global Immune Thrombocytopenic Purpura Therapeutics Consumption Forecast and Growth Rate by Type (2022-2028)

      • 10.1.1 Global Eltrombopag Olamine Consumption Forecast and Growth Rate (2022-2028)

      • 10.1.2 Global Fostamatinib Disodium Consumption Forecast and Growth Rate (2022-2028)

      • 10.1.3 Global GL-2045 Consumption Forecast and Growth Rate (2022-2028)

      • 10.1.4 Global Avatrombopag Consumption Forecast and Growth Rate (2022-2028)

      • 10.1.5 Global BI-655064 Consumption Forecast and Growth Rate (2022-2028)

      • 10.1.6 Global Others Consumption Forecast and Growth Rate (2022-2028)

    • 10.2 Global Immune Thrombocytopenic Purpura Therapeutics Consumption Forecast and Growth Rate by Application (2022-2028)

      • 10.2.1 Global Hospital Consumption Forecast and Growth Rate (2022-2028)

      • 10.2.2 Global Clinic Consumption Forecast and Growth Rate (2022-2028)

      • 10.2.3 Global Others Consumption Forecast and Growth Rate (2022-2028)

    11 Global Immune Thrombocytopenic Purpura Therapeutics Import and Export Analysis (Top 5 Countries)

    • 11.1 Global Immune Thrombocytopenic Purpura Therapeutics Import by Region (Top 5 Countries) (2017-2028)

    • 11.2 Global Immune Thrombocytopenic Purpura Therapeutics Export by Region (Top 5 Countries) (2017-2028)

    12 Coronavirus Disease (COVID-19) Impact

    • 12.1 Industry Impact Analysis

    • 12.2 Immune Thrombocytopenic Purpura Therapeutics Market Outlook to 2028 - COVID-19 Affected Forecasts

    13 Competition Matrix

    • 13.1 Target Markets

    • 13.2 Comprehensive Analysis of Products in Competitive Markets

    14 Global Immune Thrombocytopenic Purpura Therapeutics Market Competitive Analysis

    • 14.1 Baxalta Incorporated

      • 14.1.1 Baxalta Incorporated Company Details

      • 14.1.2 Baxalta Incorporated Immune Thrombocytopenic Purpura Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

      • 14.1.3 Baxalta Incorporated Immune Thrombocytopenic Purpura Therapeutics Product and Service

    • 14.2 Bristol-Myers Squibb Company

      • 14.2.1 Bristol-Myers Squibb Company Company Details

      • 14.2.2 Bristol-Myers Squibb Company Immune Thrombocytopenic Purpura Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

      • 14.2.3 Bristol-Myers Squibb Company Immune Thrombocytopenic Purpura Therapeutics Product and Service

    • 14.3 Momenta Pharmaceuticals, Inc

      • 14.3.1 Momenta Pharmaceuticals, Inc Company Details

      • 14.3.2 Momenta Pharmaceuticals, Inc Immune Thrombocytopenic Purpura Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

      • 14.3.3 Momenta Pharmaceuticals, Inc Immune Thrombocytopenic Purpura Therapeutics Product and Service

    • 14.4 Boehringer Ingelheim GmbH

      • 14.4.1 Boehringer Ingelheim GmbH Company Details

      • 14.4.2 Boehringer Ingelheim GmbH Immune Thrombocytopenic Purpura Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

      • 14.4.3 Boehringer Ingelheim GmbH Immune Thrombocytopenic Purpura Therapeutics Product and Service

    • 14.5 Amgen Inc

      • 14.5.1 Amgen Inc Company Details

      • 14.5.2 Amgen Inc Immune Thrombocytopenic Purpura Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

      • 14.5.3 Amgen Inc Immune Thrombocytopenic Purpura Therapeutics Product and Service

    • 14.6 Hansa Medical AB

      • 14.6.1 Hansa Medical AB Company Details

      • 14.6.2 Hansa Medical AB Immune Thrombocytopenic Purpura Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

      • 14.6.3 Hansa Medical AB Immune Thrombocytopenic Purpura Therapeutics Product and Service

    • 14.7 Eisai

      • 14.7.1 Eisai Company Details

      • 14.7.2 Eisai Immune Thrombocytopenic Purpura Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

      • 14.7.3 Eisai Immune Thrombocytopenic Purpura Therapeutics Product and Service

    • 14.8 Intas Pharmaceuticals Ltd

      • 14.8.1 Intas Pharmaceuticals Ltd Company Details

      • 14.8.2 Intas Pharmaceuticals Ltd Immune Thrombocytopenic Purpura Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

      • 14.8.3 Intas Pharmaceuticals Ltd Immune Thrombocytopenic Purpura Therapeutics Product and Service

    • 14.9 Pfizer Inc

      • 14.9.1 Pfizer Inc Company Details

      • 14.9.2 Pfizer Inc Immune Thrombocytopenic Purpura Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

      • 14.9.3 Pfizer Inc Immune Thrombocytopenic Purpura Therapeutics Product and Service

    • 14.10 Immunomedics, Inc

      • 14.10.1 Immunomedics, Inc Company Details

      • 14.10.2 Immunomedics, Inc Immune Thrombocytopenic Purpura Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

      • 14.10.3 Immunomedics, Inc Immune Thrombocytopenic Purpura Therapeutics Product and Service

    • 14.11 Novartis AG

      • 14.11.1 Novartis AG Company Details

      • 14.11.2 Novartis AG Immune Thrombocytopenic Purpura Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

      • 14.11.3 Novartis AG Immune Thrombocytopenic Purpura Therapeutics Product and Service

    • 14.12 Jiangsu Hengrui Medicine Co, Ltd

      • 14.12.1 Jiangsu Hengrui Medicine Co, Ltd Company Details

      • 14.12.2 Jiangsu Hengrui Medicine Co, Ltd Immune Thrombocytopenic Purpura Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

      • 14.12.3 Jiangsu Hengrui Medicine Co, Ltd Immune Thrombocytopenic Purpura Therapeutics Product and Service

    • 14.13 Merck & Co, Inc

      • 14.13.1 Merck & Co, Inc Company Details

      • 14.13.2 Merck & Co, Inc Immune Thrombocytopenic Purpura Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

      • 14.13.3 Merck & Co, Inc Immune Thrombocytopenic Purpura Therapeutics Product and Service

    15 Appendix


    TABLE OF CHARTS

    • Table Definition of Immune Thrombocytopenic Purpura Therapeutics

    • Figure Immune Thrombocytopenic Purpura Therapeutics Picture

    • Table Global Immune Thrombocytopenic Purpura Therapeutics Market Size and Forecast 2022 - 2028 (USD million)

    • Figure Global Immune Thrombocytopenic Purpura Therapeutics Market Size and Forecast 2022 - 2028 (USD million)

    • Figure Global Immune Thrombocytopenic Purpura Therapeutics Market: Year-over-year Growth 2022 - 2028 (%)

    • Table Parent Market Analysis

    • Figure Parent Market Price

    • Table Related/Ancillary Market Outlook Analysis

    • Table Supplier Power Analysis

    • Table Buyer Power Analysis

    • Table Substitution Threat Analysis

    • Table Threat of New Entrants Analysis

    • Table Competitive Rivalry Analysis

    • Figure Global Immune Thrombocytopenic Purpura Therapeutics Consumption by Country (2017-2022)

    • Figure United States Immune Thrombocytopenic Purpura Therapeutics Consumption and Growth Rate (2017-2022)

    • Table Europe Immune Thrombocytopenic Purpura Therapeutics Consumption and Growth Rate (2017-2022)

    • Figure China Immune Thrombocytopenic Purpura Therapeutics Consumption and Growth Rate (2017-2022)

    • Figure Japan Immune Thrombocytopenic Purpura Therapeutics Consumption and Growth Rate (2017-2022)

    • Figure India Immune Thrombocytopenic Purpura Therapeutics Consumption and Growth Rate (2017-2022)

    • Figure South Korea Immune Thrombocytopenic Purpura Therapeutics Consumption and Growth Rate (2017-2022)

    • Figure Global Immune Thrombocytopenic Purpura Therapeutics Consumption Forecast by Country (2022-2028)

    • Figure United States Immune Thrombocytopenic Purpura Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Table Europe Immune Thrombocytopenic Purpura Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Figure China Immune Thrombocytopenic Purpura Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Figure Japan Immune Thrombocytopenic Purpura Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Figure India Immune Thrombocytopenic Purpura Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Figure South Korea Immune Thrombocytopenic Purpura Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Eltrombopag Olamine Consumption and Growth Rate (2017-2022)

    • Figure Global Fostamatinib Disodium Consumption and Growth Rate (2017-2022)

    • Figure Global GL-2045 Consumption and Growth Rate (2017-2022)

    • Figure Global Avatrombopag Consumption and Growth Rate (2017-2022)

    • Figure Global BI-655064 Consumption and Growth Rate (2017-2022)

    • Figure Global Others Consumption and Growth Rate (2017-2022)

    • Figure Global Hospital Consumption and Growth Rate (2017-2022)

    • Figure Global Clinic Consumption and Growth Rate (2017-2022)

    • Figure Global Others Consumption and Growth Rate (2017-2022)

    • Figure Global Eltrombopag Olamine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Fostamatinib Disodium Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global GL-2045 Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Avatrombopag Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global BI-655064 Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Others Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Hospital Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Clinic Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Others Consumption Forecast and Growth Rate (2022-2028)

    • Table Global Immune Thrombocytopenic Purpura Therapeutics Import by Region (Top 5 Countries) (2017-2028)

    • Table Global Immune Thrombocytopenic Purpura Therapeutics Export by Region (Top 5 Countries) (2017-2028)

    • Table Baxalta Incorporated (Foundation Year, Company Profile and etc.)

    • Table Baxalta Incorporated Immune Thrombocytopenic Purpura Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

    • Table Baxalta Incorporated Immune Thrombocytopenic Purpura Therapeutics Product and Service

    • Table Bristol-Myers Squibb Company (Foundation Year, Company Profile and etc.)

    • Table Bristol-Myers Squibb Company Immune Thrombocytopenic Purpura Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

    • Table Bristol-Myers Squibb Company Immune Thrombocytopenic Purpura Therapeutics Product and Service

    • Table Momenta Pharmaceuticals, Inc (Foundation Year, Company Profile and etc.)

    • Table Momenta Pharmaceuticals, Inc Immune Thrombocytopenic Purpura Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

    • Table Momenta Pharmaceuticals, Inc Immune Thrombocytopenic Purpura Therapeutics Product and Service

    • Table Boehringer Ingelheim GmbH (Foundation Year, Company Profile and etc.)

    • Table Boehringer Ingelheim GmbH Immune Thrombocytopenic Purpura Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

    • Table Boehringer Ingelheim GmbH Immune Thrombocytopenic Purpura Therapeutics Product and Service

    • Table Amgen Inc (Foundation Year, Company Profile and etc.)

    • Table Amgen Inc Immune Thrombocytopenic Purpura Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

    • Table Amgen Inc Immune Thrombocytopenic Purpura Therapeutics Product and Service

    • Table Hansa Medical AB (Foundation Year, Company Profile and etc.)

    • Table Hansa Medical AB Immune Thrombocytopenic Purpura Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

    • Table Hansa Medical AB Immune Thrombocytopenic Purpura Therapeutics Product and Service

    • Table Eisai (Foundation Year, Company Profile and etc.)

    • Table Eisai Immune Thrombocytopenic Purpura Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

    • Table Eisai Immune Thrombocytopenic Purpura Therapeutics Product and Service

    • Table Intas Pharmaceuticals Ltd (Foundation Year, Company Profile and etc.)

    • Table Intas Pharmaceuticals Ltd Immune Thrombocytopenic Purpura Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

    • Table Intas Pharmaceuticals Ltd Immune Thrombocytopenic Purpura Therapeutics Product and Service

    • Table Pfizer Inc (Foundation Year, Company Profile and etc.)

    • Table Pfizer Inc Immune Thrombocytopenic Purpura Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

    • Table Pfizer Inc Immune Thrombocytopenic Purpura Therapeutics Product and Service

    • Table Immunomedics, Inc (Foundation Year, Company Profile and etc.)

    • Table Immunomedics, Inc Immune Thrombocytopenic Purpura Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

    • Table Immunomedics, Inc Immune Thrombocytopenic Purpura Therapeutics Product and Service

    • Table Novartis AG (Foundation Year, Company Profile and etc.)

    • Table Novartis AG Immune Thrombocytopenic Purpura Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

    • Table Novartis AG Immune Thrombocytopenic Purpura Therapeutics Product and Service

    • Table Jiangsu Hengrui Medicine Co, Ltd (Foundation Year, Company Profile and etc.)

    • Table Jiangsu Hengrui Medicine Co, Ltd Immune Thrombocytopenic Purpura Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

    • Table Jiangsu Hengrui Medicine Co, Ltd Immune Thrombocytopenic Purpura Therapeutics Product and Service

    • Table Merck & Co, Inc (Foundation Year, Company Profile and etc.)

    • Table Merck & Co, Inc Immune Thrombocytopenic Purpura Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

    • Table Merck & Co, Inc Immune Thrombocytopenic Purpura Therapeutics Product and Service


Report Version Choose

Report

BUY NOW

Our Customers

Beyond grateful for the confidence and support from all partners and customers.A win-win situation is our ultimate pursuit.

Beyond Consulting, Future is Feasible

We provide more professional and intelligent market reports to complement your business decisions.

CONTACT US